Type 2 Diabetes Clinical Trial
Official title:
Genetic Contribution to the Pathophysiology of the Charcot Foot in Qatari Patients With Diabetes
To assess the hypothesis that Charcot foot is associated with more vascular complications compared to matched diabetic patients without Charcot foot and to classify patients with Charcot foot according to the human genetic classification of the Qatari population.
Diabetes is a serious health issue for the Qatari population since approximately 1/5 of the
population has Type 2 Diabetes, which is 2-3 times higher than the world average. Although
much of the clinical studies of diabetes often focused on microvascular phenotypes such as
retinopathy and nephropathy, and macrovascular diseases presenting clinically as myocardial
infarction, stroke, and peripheral vascular disease, other rare complications such as Charcot
foot disease confer a significant burden in Qatar diabetic population, leading to decreased
life quality.
Charcot foot is estimated to affect 0.8% to 8% of diabetic populations. It occurs most
commonly in patients with diabetes complicated by severe peripheral neuropathy, often with
coexisting sympathetic denervation, causing increased blood flow to the foot and increased
bone resorption.
Uncontrolled and inappropriate inflammation leading to bone resorption and deformation has
been the hallmark of diabetic Charcot foot pathophysiology. There are two major theories that
provide the likely mechanism of the disease. The "neurovascular (French) theory" suggests
that increased blood flow, as a result of autonomic neuropathy, can lead to bone destruction
and mechanical debilitation. On the other hand, the "neurotraumatic (German) theory" argues
that the loss of protective sensation leads to unperceived injury and trauma in the insensate
foot. One can argue that the pathogenesis of Charcot neuro-arthropathy is most likely a
combination of these processes. For unknown reasons, Charcot foot is trigged only in some
susceptible individuals with diabetes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |